About
Dominick DiSabatino is a partner on the Life Sciences team in the firm's Washington, D.C. office.
Oregon Prescription Drug Price Transparency Act in Limbo
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI®
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI®
OIG Permits Medical Device Manufacturer’s Cost-Sharing Subsidies for Medicare Beneficiaries in Clinical Trial
2024 Top-of-Mind Issues for Life Sciences Companies
2024 Top-of-Mind Issues for Life Sciences Companies
FDA Issues Final Rule and Guidance on Direct-To-Consumer Prescription Drug Advertisements
From Good Reprint Practices to SIUU Communications: What Firms Need to Know
OIG General Compliance Program Guidance November 2023
About
Dominick DiSabatino is a partner on the Life Sciences team in the firm's Washington, D.C. office.
Blogs